Actively Recruiting
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
Led by University of Alabama at Birmingham · Updated on 2026-05-05
70
Participants Needed
1
Research Sites
65 weeks
Total Duration
On this page
Sponsors
U
University of Alabama at Birmingham
Lead Sponsor
M
Merck Sharp & Dohme LLC
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria. We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.
CONDITIONS
Official Title
Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy adult
You will not qualify if you...
- No prior history of pneumococcal vaccination
- No immunosuppressing medications or chronic diseases that affect immune function
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294
Actively Recruiting
Research Team
D
David LaFon, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here